Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crystalvue Medical CoROCO:6527 -2.07%94 EV-to-EBITDA is 9.50 as of Sep. 12, 2026, which is 4% below its 10-year median of 9.87. GuruFocus rates ROCO:6527 with a GF Score™ of 94/100 and a GF Value™ of NT$85.92 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Crystalvue Medical Co ranks better than 65.89% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Crystalvue Medical Co's enterprise value is NT$1,875.2 Mil.
Crystalvue Medical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$197.4 Mil. Therefore, Crystalvue Medical Co's EV-to-EBITDA for today is 9.50.
The historical rank and industry rank for Crystalvue Medical Co's EV-to-EBITDA or its related term are showing as below:
ROCO:6527'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.88 Med: 9.87 Max: 31.7
Current: 9.5
During the past 13 years, the highest EV-to-EBITDA of Crystalvue Medical Co was 31.70. The lowest was 2.88. And the median was 9.87.
ROCO:6527's EV-to-EBITDA is ranked better than 65.89% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 13.675
vs ROCO:6527: 9.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Crystalvue Medical Co (ROCO:6527) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Crystalvue Medical Co's PE Ratio (TTM) for today is calculated as:
Crystalvue Medical Co's share price for today is NT$75.80.
Crystalvue Medical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$5.785.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Crystalvue Medical Co EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Crystalvue Medical Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6527 vs ISRG, BDX, RMD: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Crystalvue Medical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crystalvue Medical Co EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Crystalvue Medical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Crystalvue Medical Co's EV-to-EBITDA falls into.
Crystalvue Medical Co's current Enterprise Value is NT$1,875.2 Mil.
Crystalvue Medical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$197.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crystalvue Medical Co (ROCO:6527) has a EV-to-EBITDA of 9.50 as of Sep. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Crystalvue Medical Co. This is near median its historical median of 9.87. Over the past decade, Crystalvue Medical Co's EV-to-EBITDA has ranged from 2.88 to 31.70. According to the industry distribution chart, Crystalvue Medical Co ranks #176 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 34.1%.
Is Crystalvue Medical Co's EV-to-EBITDA too high?
Crystalvue Medical Co's current EV-to-EBITDA of 9.50 is near median its 10-year median of 9.87. Over the past 10 years, this metric has ranged from a low of 2.88 to a high of 31.70. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.68. Crystalvue Medical Co's value of 9.50 is 30.5% below this industry median. Based on the distribution chart, Crystalvue Medical Co ranks #176 out of 516 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Crystalvue Medical Co has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Crystalvue Medical Co's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Crystalvue Medical Co ranks #176 out of 516 companies for EV-to-EBITDA. This puts Crystalvue Medical Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.68. Crystalvue Medical Co's value of 9.50 is 30.5% below this benchmark. Historically, Crystalvue Medical Co's own EV-to-EBITDA has ranged from 2.88 to 31.70 over the past decade. While the company's 10-year median is 9.87 vs. the industry median of 13.68, Crystalvue Medical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.68, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crystalvue Medical Co's current EV-to-EBITDA of 9.50 is 30.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Crystalvue Medical Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crystalvue Medical Co's current EV-to-EBITDA is 9.50, which is near median its own 10-year median of 9.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crystalvue Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Crystalvue Medical Co (ROCO:6527) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.92, compared to a current price of NT$75.80 — trading 11.8% below its estimated fair value. The current EV-to-EBITDA is 9.50, which is near median its 10-year median of 9.87 and 30.5% below the Medical Devices & Instruments industry median of 13.68. Crystalvue Medical Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Crystalvue Medical Co (ROCO:6527), the current EV-to-EBITDA is 9.50 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crystalvue Medical Co (ROCO:6527) Overvalued in 2026?
Based on GuruFocus' analysis, Crystalvue Medical Co stock appears to be undervalued.
The current stock price of NT$75.80 is trading 11.8% below its estimated GF Value™ of NT$85.92.
GuruFocus considers Crystalvue Medical Co to be Modestly Undervalued.
Key valuation signals for ROCO:6527:
EV-to-EBITDA: 9.50 (near median its 10-year median of 9.87)
GF Value™: NT$85.92 vs. price of NT$75.80 (11.8% below fair value)
Industry Position: 30.5% below the Medical Devices & Instruments median (#176 of 516)
No single metric tells the full story. See the ROCO:6527 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crystalvue Medical Co Ltd is engaged in the manufacture and sale of medical devices. Its products include fundus cameras, optical coherence tomography (OCT) systems, tonometers, digital microscope cameras, lens edgers, and gastrointestinal endoscopic disposable devices, among others.
94GF Score
Get the complete analysis for ROCO:6527
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6527 has been successfully added to your 
